COVID-19News

MSN Labs enters into licensing agreement with Lilly

Baricitinib (BARIDOZ) will be launched in India for COVID-19 treatment

MSN Labs has entered into a royalty-free, non-exclusive, voluntary license agreement with Eli Lilly and Company of USA for manufacturing and marketing of baricitinib for COVID-19 in India.

THIS CAN BE YOUR ADVERTISEMENT

The drug baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization for emergency use in combination with remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 

Dr MSN Reddy, CMD – MSN Group, commented “This collaboration with Eli Lilly and company is a landmark milestone in India’s fight against COVID-19 and will thus help in increasing the availability and affordability of baricitinib”.

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close